Although silencing NLRP1 or NLRP3 could theoretically reduce the risk of squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) by diminishing chronic inflammation and altering the immune microenvironment, further research is essential to comprehensively elucidate their roles and the implications of such interventions. This evidence concerns the gene NLRP3 and basal cell carcinoma.